1.Bartsch H, Rojas M, Nair U, Nair J & Alexandrov K (1999) Genetic cancer susceptibility and DNA adducts: studies in smokers, tobacco chewers, and coke oven workers. Cancer Detect Prev 23, 445–453.
2.IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2004) Betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum 85, 1–334.
3.Tsai JF, Jeng JE, Chuang LY et al. (2003) Habitual betel quid chewing as a risk factor for cirrhosis: a case–control study. Medicine (Baltimore) 82, 365–372.
4.Tsai JF, Chuang LY, Jeng JE, Ho MS, Hsieh MY, Lin ZY & Wang LY (2001) Betel quid chewing as a risk factor for hepatocellular carcinoma: a case–control study. Br J Cancer 84, 709–713.
5.Wang LY, You SL, Lu SN, Ho HC, Wu MH, Sun CA, Yang HI & Chien-Jen C (2003) Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 14, 241–250.
6.Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, Wu MH & Chen CJ (2003) Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 157, 674–682.
7.Prokopczyk B, Rivenson A, Bertinato P, Brunnemann KD & Hoffmann D (1987) 3-(Methylnitrosamino)propionitrile: occurrence in saliva of betel quid chewers, carcinogenicity, and DNA methylation in F344 rats. Cancer Res 47, 467–471.
8.Raisuddin S & Misra JK (1991) Aflatoxin in betel nut and its control by use of food preservatives. Food Addit Contam 8, 707–712.
9.Chen THH, Chiu YH, Luh DL et al. Taiwan Community-Based Integrated Screening Group (2004) Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer 100, 1734–1743.
10.Chen THH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, Yang PM, Lee HS & Duffy SW (2002) Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 98, 257–261.
11.Ahmad OE, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R & Inoue M (2000) Age Standardization of Rates: A New WHO Standard. GPE Discussion Paper Series no. 31. Geneva: WHO.
12.Hosmer DW & Lemeshow S (1992) Confidence interval estimation of interaction. Epidemiology 3, 452–456.
13.Srivatanakul P, Parkin DM, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S, L'Abbé KA & Wild CP (1991) Liver cancer in Thailand. II. A case–control study of hepatocellular carcinoma. Int J Cancer 48, 329–332.
14.Liu CJ, Chen CL, Chang KW, Chu CH & Liu TY (2000) Safrole in betel quid may be a risk factor for hepatocellular carcinoma: case report. CMAJ 162, 359–360.
15.Trivedy C, Meghji S, Warnakulasuriya KA, Johnson NW & Harris M (2001) Copper stimulates human oral fibroblasts in vitro: a role in the pathogenesis of oral submucous fibrosis. J Oral Pathol Med 30, 465–470.
16.Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ & Warnakulasuriya S (2006) Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42, 561–568.
17.Chang YC, Yang SF, Tai KW, Chou MY & Hsieh YS (2002) Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol 38, 195–200.
18.Lichtinghagen R, Michels D, Haberkorn CI, Arndt B, Bahr M, Flemming P, Manns MP & Boeker KH (2001) Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 34, 239–247.
19.Flisiak R, Maxwell P, Prokopowicz D, Timms PM & Panasiuk A (2002) Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor β1 – possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepatogastroenterology 49, 1369–1372.
20.Shieh DH, Chiang LC & Shieh TY (2003) Augmented mRNA expression of tissue inhibitor of metalloproteinase-1 in buccal mucosal fibroblasts by arecoline and safrole as a possible pathogenesis for oral submucous fibrosis. Oral Oncol 39, 728–735.
21.Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP & Boucher BJ (2002) Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 95, 787–796.
22.Bataller R, Sancho-Bru P, Gines P & Brenner DA (2005) Liver fibrogenesis: a new role for the renin–angiotensin system. Antioxid Redox Signal 7, 1346–1355.
23.Yokohama S, Tokusashi Y, Nakamura K et al. (2006) Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 12, 322–326.
24.Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S & Fukui H (2002) Inhibition of renin–angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 37, 22–30.
25.Basak R, Bhattacharya R & Chatterjee M (2001) 1α,25-Dihydroxyvitamin D(3) inhibits rat liver ultrastructural changes in diethylnitrosamine-initiated and phenobarbital promoted rat hepatocarcinogenesis. J Cell Biochem 81, 357–367.
26.Douds AC, Cox MA, Iqbal TH & Cooper BT (2003) Ethnic differences in cirrhosis of the liver in a British city: alcoholic cirrhosis in South Asian men. Alcohol Alcohol 38, 148–150.
27.Haworth EA, Soni Raleigh V & Balarajan R (1999) Cirrhosis and primary liver cancer amongst first generation migrants in England and Wales. Ethn Health 4, 93–99.
28.Boucher BJ (1998) Inadequate vitamin D status: does it contribute to the disorders comprising syndrome ‘X’? Br J Nutr 79, 315–327.
29.Awumey EM, Mitra DA, Hollis BW, Kumar R & Bell NH (1998) Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study. J Clin Endocrinol Metab 83, 169–173.
30.Chiang CP, Huang JS, Wang JT, Liu BY, Kuo YS, Hahn LJ & Kuo MY (1999) Expression of p53 protein correlates with decreased survival in patients with areca quid chewing and smoking-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 28, 72–76.
31. Ogunkolade WB, Boucher BJ, Bustin SA, Burrin JM, Noonan K, Mannan N & Hitman GA (2006) Vitamin D metabolism in peripheral blood mononuclear cells is influenced by chewing ‘betel-nut’ (Areca catechu) and vitamin D status. J Clin Endocrinol Metab 91, 2612–2617.
32.Wong YK, Liu TY, Chang KW, Lin SC, Chao TW, Li PL & Chang CS (1998) p53 alterations in betel quid- and tobacco-associated oral squamous cell carcinomas from Taiwan. J Oral Pathol Med 27, 243–248.
33.Baral R, Patnaik S & Das BR (1998) Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Eur J Oral Sci 106, 907–913.
34.Kuo MY, Lin CY, Hahn LJ, Cheng SJ & Chiang CP (1999) Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 28, 165–169.
35.Wen CP, Tsai SP, Cheng TY, Chen CJ, Levy DT, Yang HJ & Eriksen MP (2005) Uncovering the relation between betel quid chewing and cigarette smoking in Taiwan. Tob Control 14, Suppl. 1, i16–i22.
36.Leon DA & McCambridge J (2006) Liver cirrhosis mortality rates in Britain, 1950–2002, an analysis of routine data. Lancet 367, 52–56.
37.Boucher BJ & Mannan N (2002) Metabolic effects of the consumption of Areca catechu. Addict Biol 7, 103–110.